转移性头颈鳞癌免疫治疗的真实世界治疗模式
基于美国大型理赔数据库2016至2017年数据,纳入416例接受免疫肿瘤(IO)治疗的转移性头颈鳞状细胞癌(mHNSCC)患者,描述IO治疗前后的治疗模式。
要点
- 85%的mHNSCC患者在IO治疗前已接受过至少一种方案。
- 28%患者有后续方案,其中50%为化疗、23%为IO单药。
核心结论
- 大多数mHNSCC患者以IO单药起始治疗。
- 有后续方案的患者中约半数接受化疗、约四分之一接受IO单药。
研究设计与样本
- 基于美国大型理赔数据库2016至2017年的回顾性描述性研究。
- 纳入416例接受IO治疗的mHNSCC患者。
主要发现
- 416例患者中85%在IO治疗前有至少一种方案。
- 27例IO单药后续中22例重启同一IO治疗、5例换用另一种IO单药。
临床怎么用
- 真实世界中mHNSCC的IO治疗以单药为主,联合治疗少见。
- 后续治疗中化疗和IO单药是主要选择,需关注IO重启或换药策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Real-world use of immuno-oncology (IO) therapies (nivolumab and pembrolizumab) in metastatic head and neck squamous cell carcinoma (mHNSCC) has not been well studied. METHODS: mHNSCC patients treated with an IO therapy were identified from a large US claims database from 2016 to 2017. Treatment patterns before and after initiation of IO therapy (index date) were described. RESULTS: Among 416 mHNSCC patients, 85% had ≥1 regimen prior to IO therapy. Ninety-seven percent of patients initiated IO as monotherapy and 3% initiated IO combined with another systemic treatment. One hundred seventeen (28%) patients had a subsequent regimen, usually chemotherapy (n = 58, 50%) or IO monotherapy (n = 27, 23%), of which 22 patients restarted the same IO therapy and 5 switched to another IO monotherapy. CONCLUSION: The majority of mHNSCC patients initiated IO as a monotherapy. Approximately half of patients with a subsequent regimen received chemotherapy and one-fourth received IO monotherapy.
引用
- Mehra R, Huang H, Seal B, et al. Real-world treatment patterns for patients with metastatic head and neck squamous cell carcinoma treated with immuno-oncology therapy. Head Neck. 2020. PMID: 32149458. doi:10.1002/hed.26126
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。